Literature DB >> 23964555

A polymorphism in ORMDL3 is associated not only with asthma without rhinitis but also with chronic obstructive pulmonary disease.

M Balantic1, M Rijavec, M Flezar, T Camlek, I Hudoklin, M Kosnik, P Korosec, S Suskovic.   

Abstract

BACKGROUND: Asthma is a heterogeneous disease, and asthmatic patients without rhinitis more commonly have fixed airway obstruction, a feature that is also typical of chronic obstructive pulmonary disease (COPD). The Dutch hypothesis suggests that both COPD and asthma have common genetic risk factors. The purpose of this study was to assess the association between the polymorphism rs4795405 in the known asthma candidate gene ORMDL3 and asthma with and without rhinitis. We also analyzed COPD in order to investigate whether, in addition to a clinical overlap, there might also be a genetic overlap between COPD and asthma.
METHODS: The population of this genetic association study comprised 493 Slovenian adults, distributed as follows: 131 patients with asthma (59 had asthma with rhinitis and 72 asthma without rhinitis), 59 patients with rhinitis only, 133 patients with COPD, and 170 controls. Genotypes for rs4795405 were determined using the TaqMan genotyping assay.
RESULTS: rs4795405 was specifically associated with asthma without rhinitis. Assuming a recessive genetic model, we found the CC genotype in 26% of healthy controls, in 24% of patients with asthma with rhinitis (P = .862), and in 44% of patients with asthma without rhinitis (P = .006). Polymorphism rs4795405 was also associated with COPD, for which the CC genotype was found in 37% of cases (P = .045).
CONCLUSIONS: rs4795405 was strongly associated with asthma without rhinitis, a subtype of asthma for which a higher degree of airway obstruction was found. These results show the importance of analyzing different asthma phenotypes in genetic association studies. We also observed a genetic overlap between COPD and asthma without rhinitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23964555

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  6 in total

1.  Aryl hydrocarbon receptor signaling promotes ORMDL3-dependent generation of sphingosine-1-phosphate by inhibiting sphingosine-1-phosphate lyase.

Authors:  Hsueh-Chun Wang; Tzu-Hsuan Wong; Li-Ting Wang; Hsiang-Han Su; Hsiu-Yueh Yu; Ai-Hsuan Wu; Yu-Chun Lin; Hua-Ling Chen; Jau-Ling Suen; Shih-Hsien Hsu; Li-Chen Chen; Yufeng Zhou; Shau-Ku Huang
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

Review 2.  Unraveling the Pathogenesis of Asthma and Chronic Obstructive Pulmonary Disease Overlap: Focusing on Epigenetic Mechanisms.

Authors:  Yung-Che Chen; Yu-Ping Chang; Kuo-Tung Huang; Po-Yuan Hsu; Chang-Chun Hsiao; Meng-Chih Lin
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

3.  Variation in doses and duration of particulate matter exposure in bronchial epithelial cells results in upregulation of different genes associated with airway disorders.

Authors:  Priya Tripathi; Furong Deng; Anne M Scruggs; Yahong Chen; Steven K Huang
Journal:  Toxicol In Vitro       Date:  2018-05-09       Impact factor: 3.500

4.  Negative regulatory roles of ORMDL3 in the FcεRI-triggered expression of proinflammatory mediators and chemotactic response in murine mast cells.

Authors:  Viktor Bugajev; Ivana Halova; Lubica Draberova; Monika Bambouskova; Lucie Potuckova; Helena Draberova; Tomas Paulenda; Sergi Junyent; Petr Draber
Journal:  Cell Mol Life Sci       Date:  2015-09-25       Impact factor: 9.261

Review 5.  Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma.

Authors:  Pinja Ilmarinen; Leena E Tuomisto; Hannu Kankaanranta
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

6.  ORMDL3 overexpression facilitates FcεRI-mediated transcription of proinflammatory cytokines and thapsigargin-mediated PERK phosphorylation in RBL-2H3 cells.

Authors:  Kazuhiro Ogi; Tetsuji Takabayashi; Kaori Tomita; Masafumi Sakashita; Taiyo Morikawa; Takahiro Ninomiya; Masayuki Okamoto; Norihiko Narita; Shigeharu Fujieda
Journal:  Immun Inflamm Dis       Date:  2021-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.